Observational studyBMC cancer2026

First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status.

Chang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.